----
Current ValuationThe current P/E ratio is -704.42, within the reasonable range, cheaper than 99.62% of the time in the past 1 years, and the industry ranks 73/74, the industry Median --.
-704.42xP/E
--Stock price
-704.42xP/E
Stock price--
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -704.42x
- Typical range
- -704.42x–-704.42x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -47.97x | 2.97% | $21.75B |
HIMSUSHims & Hers Health | -48.80x | 209.86% | $6.93B |
RDNTUSRadnet | -266.51x | 128.00% | $5.63B |
NEOUSNeogenomics | -41.26x | 64.12% | $2.14B |
WGSUSGeneDx | -18.21x | 359.59% | $1.94B |
AGLUSagilon health | -6.21x | 92.48% | $1.44B |
INNVUSInnovage | -485.14x | 2,301.70% | $1.23B |
LMRIUSLumexa Imaging | -36.76x | 145.51% | $1.02B |
CSTLUSCastle Biosciences | -51.74x | 51.54% | $1.00B |
OPKUSOpko Health | -13.52x | 25.99% | $985.15M |
FLGTUSFulgent Genetics | -6.87x | 42.64% | $579.47M |
GMRSUSGMR Solutions | -7.56x | 91.45% | $572.09M |
PREUSPrenetics Global | -7.76x | 15.02% | $364.64M |
BDSXUSBiodesix | -9.50x | 42.77% | $263.78M |
GAMGUSGlobal Asset Management Group, Inc. | -382.76x | -- | $216.04M |
NAKAUSNakamoto | -0.37x | 102.50% | $153.54M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $127.35M |
AIRSUSAirSculpt Tech | -9.95x | 33.33% | $116.79M |
PARKUSPark Dental Partners | -26.35x | -- | $93.16M |
EUDAUSEuda Health | -21.55x | 208.11% | $50.93M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
